Quotes 5-day view Delayed Nyse
10/26/2020
10/27/2020
10/28/2020
10/29/2020
10/30/2020
Date
141.7(c)
131.9(c)
131.31(c)
132.55(c)
130.46(c)
Last
2 947 097
11 374 611
6 188 028
4 099 914
4 296 423
Volume
-0.48% -6.92% -0.45% +0.94% -1.58% Change
Sales 2020
23 723 M - -
Net income 2020
6 107 M - -
Net Debt 2020
11 184 M - -
P/E ratio 2020
20,2x
Yield 2020
2,27%
Sales 2021
25 927 M - -
Net income 2021
7 254 M - -
Net Debt 2021
8 770 M - -
P/E ratio 2021
16,5x
Yield 2021
2,50%
Capitalization
120 B 120 B -
EV / Sales 2020
5,54x
EV / Sales 2021
4,97x
Nbr of Employees
33 625
Free-Float
99,8%
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both...
Notations Surperformance© of Eli Lilly and Company
Trading Rating : Investor Rating :
All news about ELI LILLY AND COMPANY
News in other languages on ELI LILLY AND COMPANY
S&P 500, Dow slip on worries about earnings, U.S. stimulus outlook
Chart ELI LILLY AND COMPANY
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ELI LILLY AND COMPANY
Short Term Mid-Term Long Term Trends Bearish Bearish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
19
Average target price
165,83 $
Last Close Price
130,46 $
Spread / Highest target
53,3%
Spread / Average Target
27,1%
Spread / Lowest Target
-8,02%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
